104 related articles for article (PubMed ID: 38740045)
1. Leveraging the pleural space for anticancer therapies in pleural mesothelioma.
Blyth KG; Adusumilli PS; Astoul P; Darlison L; Lee YCG; Mansfield AS; Marciniak SJ; Maskell N; Panou V; Peikert T; Rahman NM; Zauderer MG; Sterman D; Fennell DA
Lancet Respir Med; 2024 Jun; 12(6):476-483. PubMed ID: 38740045
[TBL] [Abstract][Full Text] [Related]
2. Intrapleural Anticancer Therapy for Malignant Pleural Diseases: Facts or Fiction?
Agrawal A; Chaddha U; Shojaee S; Maldonado F
Semin Respir Crit Care Med; 2023 Aug; 44(4):462-467. PubMed ID: 37308112
[TBL] [Abstract][Full Text] [Related]
3. Intrapleural Hyaluronidase in Viscous Malignant Mesothelioma Pleural Effusion.
Foo CT; Paterson A; Duckworth A; Herre J
Chest; 2021 Dec; 160(6):e609-e611. PubMed ID: 34872672
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on the Treatment of Malignant Pleural Mesothelioma.
Janes SM; Alrifai D; Fennell DA
N Engl J Med; 2021 Sep; 385(13):1207-1218. PubMed ID: 34551230
[No Abstract] [Full Text] [Related]
5. Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
Matsuzaki Y; Tomita M; Shimizu T; Hara M; Ayabe T; Onitsuka T
Ann Thorac Cardiovasc Surg; 2008 Jun; 14(3):161-5. PubMed ID: 18577894
[TBL] [Abstract][Full Text] [Related]
6. Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy.
Murthy V; Katzman D; Sterman DH
Clin Respir J; 2019 May; 13(5):272-279. PubMed ID: 30810270
[TBL] [Abstract][Full Text] [Related]
7. [Malignant pleural mesothelioma in 1997].
Viallat JR; Boutin C; Kasseyet S
Schweiz Med Wochenschr; 1997 Oct; 127(41):1707-11. PubMed ID: 9441378
[TBL] [Abstract][Full Text] [Related]
8. Current approach to malignant mesothelioma of the pleura.
Aisner J
Chest; 1995 Jun; 107(6 Suppl):332S-344S. PubMed ID: 7781415
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and treatment of malignant pleural mesothelioma.
Rodríguez Panadero F
Arch Bronconeumol; 2015 Apr; 51(4):177-84. PubMed ID: 25059587
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous seeding after ultrasound-guided placement of intrapleural catheter. An unusual complication of the intracavitary palliative treatment of pleural mesothelioma.
Sartori S; Nielsen I; Trevisani L; Tassinari D; Abbasciano V
Support Care Cancer; 1999 Sep; 7(5):362-4. PubMed ID: 10483823
[TBL] [Abstract][Full Text] [Related]
11. Novel intrapleural therapies for malignant diseases.
Haas AR; Sterman DH
Respiration; 2012; 83(4):277-92. PubMed ID: 22456231
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma.
Tsao AS; Mehran R; Roth JA
Clin Lung Cancer; 2009 Jan; 10(1):36-41. PubMed ID: 19289370
[TBL] [Abstract][Full Text] [Related]
13. Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group.
Kaplan MA; Şendur MAN; Cangır AK; Fırat P; Göker E; Kılıçkap S; Oyan B; Büge Öz A; Özdemir F; Özyiğit G
Curr Probl Cancer; 2023 Dec; 47(6):101017. PubMed ID: 37845104
[TBL] [Abstract][Full Text] [Related]
14. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
Sterman DH; Recio A; Carroll RG; Gillespie CT; Haas A; Vachani A; Kapoor V; Sun J; Hodinka R; Brown JL; Corbley MJ; Parr M; Ho M; Pastan I; Machuzak M; Benedict W; Zhang XQ; Lord EM; Litzky LA; Heitjan DF; June CH; Kaiser LR; Vonderheide RH; Albelda SM; Kanther M
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4456-66. PubMed ID: 17671130
[TBL] [Abstract][Full Text] [Related]
15. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
Castagneto B; Zai S; Mutti L; Lazzaro A; Ridolfi R; Piccolini E; Ardizzoni A; Fumagalli L; Valsuani G; Botta M
Lung Cancer; 2001; 31(2-3):303-10. PubMed ID: 11165411
[TBL] [Abstract][Full Text] [Related]
16. High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses.
Lerza R; Esposito M; Vannozzi M; Bottino GB; Bogliolo G; Pannacciulli I
Cancer; 1994 Jan; 73(1):79-84. PubMed ID: 8275441
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].
Chen WH; Zhang XL; Dai HP; Tong ZH; Zhang YH; Jin ML
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Nov; 36(11):825-8. PubMed ID: 24507393
[TBL] [Abstract][Full Text] [Related]
18. Commentary: Assessing tumor stage and treatment response in pleural mesothelioma: Are pleural thickness measurements the new standard?
Rusch VW
J Thorac Cardiovasc Surg; 2023 Aug; 166(2):372-373. PubMed ID: 36732146
[No Abstract] [Full Text] [Related]
19. Curcumin as an Anticancer Agent in Malignant Mesothelioma: A Review.
Baldi A; De Luca A; Maiorano P; D'Angelo C; Giordano A
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32155978
[TBL] [Abstract][Full Text] [Related]
20. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
Rusch VW; Niedzwiecki D; Tao Y; Menendez-Botet C; Dnistrian A; Kelsen D; Saltz L; Markman M
J Clin Oncol; 1992 Jun; 10(6):1001-6. PubMed ID: 1588364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
